Asieris’ APL-1501 Approved for Phase I Clinical Trial in Australia
SHANGHAI, Oct. 28, 2020 /PRNewswire/ -- Asieris Pharmaceuticals, a China-based biotech company specializing in the development and commercialization of new drugs…
Read More...
Read More...